Ones To Watch News
Refine Search
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Biotechnology
US antibody specialist SAB Biotherapeutics yesterday announced that SAB-176, its investigational therapeutic for the treatment of seasonal influenza, achieved statistically significant (p = 0.026) reductions in viral load and clinical signs and symptoms compared to placebo in a Phase IIa challenge study. 2 December 2021
Biotechnology
Canada and USA-based biotech Chinook Therapeutics today announced the formation of SanReno Therapeutics, a joint venture with an investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China, to develop, manufacture and commercialize kidney disease therapies in China, Hong Kong, Macau, Taiwan and Singapore (the Territory). 30 November 2021
Pharmaceutical
Specialty drugmaker Fennec Pharmaceuticals has announced it will receive a Complete Response Letter (CRL) from the US regulator for its medicine Pedmark (sodium thiosulfate). 30 November 2021
Biotechnology
US gene therapy company Krystal Biotech saw its shares skyrocket more than 120% to $88.24 by close of trading yesterday, after it announced positive top-line results from the pivotal GEM-3 trial of investigational beremagene geperpavec (B-VEC), now known as Vyjuvek, for the treatment of dystrophic epidermolysis bullosa (dystrophic EB). 30 November 2021
Biotechnology
US precision cancer therapy specialist Blueprint Medicines today announced that it has entered into a definitive agreement to acquire Lengo Therapeutics, a privately held precision oncology company. 29 November 2021
Biotechnology
London, UK-based cell therapy specialist Quell Therapeutics today announced it has raised $156 million in an oversubscribed Series B financing,. 29 November 2021
Pharmaceutical
US RNA-targeted drug developer Ionis Pharmaceuticals announced on Wednesday that partner Pfizer has provided an update on the Phase IIb study of vupanorsen, formerly IONIS-ANGPTL3-LRx. 26 November 2021
Biotechnology
The UK subsidiary of Italian family-owned Chiesi Farmaceutici announced yesterday that pegunigalsidase alfa (PRX-102) was awarded Innovation Passport status by the UK Medicines and Healthcare products Regulatory Agency (MHRA) on August 25, 021. 26 November 2021
Biotechnology
mTOR pathway specialist Aadi Bioscience has secured US approval for its intravenously-administered oncology therapy Fyarro (sirolimus). 24 November 2021
Biotechnology
The European Commission (EC) has approved Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy, says Chinese biotech BeiGene. 24 November 2021
Pharmaceutical
The US Food and Drug Administration has extended the review period for the New Drug Application (NDA) for Oleogel-S10 for the treatment of the cutaneous manifestations of junctional and dystrophic bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. 24 November 2021
Pharmaceutical
The US Food and Drug Administration on Friday approved Voxzogo (vosoritide) injection to improve growth in children five years of age and older with achondroplasia and open epiphyses (growth plates), meaning these children still have the potential to grow. Achondroplasia is the most common form of dwarfism. 20 November 2021
Biotechnology
The European Commission (EC) has granted conditional marketing authorization for Gavreto (pralsetinib) as a monotherapy for the treatment of adults with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. 20 November 2021
Biotechnology
Cytokine immunotherapy company Bright Peak Therapeutics has in-licensed a checkpoint blocker from Guangdong, China-based biotech Livzon Mabpharm. 17 November 2021
Pharmaceutical
In recent weeks, stellar results from Merck & Co and from Pfizer have elevated expectations for the potential of antivirals to treat coronavirus disease. 17 November 2021
Biotechnology
US DNA synthesis firm Twist Bioscience has launched Revelar Biotherapeutics, an independently operated, new biotechnology company to develop and commercialize an antibody, discovered and optimized by its Twist Biopharma division, that neutralizes all known variants of concern of the SARS-CoV-2 virus in pre-clinical studies. 16 November 2021
Pharmaceutical
Dutch fatty acid expert NorthSea Therapeutics has presented positive interim data from a Phase IIb study of its non-alcoholic steatohepatitis (NASH) candidate, icosabutate. 16 November 2021
Biotechnology
Australian off-the-shelf cell therapy specialist Mesoblast saw its shares gain nearly 12% to A$1.90 today, as it released positive new results from the landmark Phase III study of rexlemestrocel-L in 565 patients with chronic heart failure (CHF) with reduced ejection fraction (HFrEF). 15 November 2021
Biotechnology
US biotech Adagio Therapeutics, which is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, today provided an update on its lead COVID-19 antibody program, ADG20. 15 November 2021
Pharmaceutical
Spanish drugmaker PharmaMar has entered a licensing agreement with Taiwan’s Lotus Pharmaceutical to commercialize the anticancer drug lurbinectedin in Taiwan. 15 November 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze